Koh Tadokoro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koh Tadokoro has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Mami Takemoto
Department of Neurology Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Okayama Japan
26 shared publications- Toru Yamashita
Department of Neurology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
24 shared publications Nozomi Hishikawa
Department of Neurology Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
22 shared publicationsYasuyuki Ohta
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho, Kita-ku, Okayama 700-8558, Japan
15 shared publicationsYoshio Omote
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
15 shared publications- Emi Nomura
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
10 shared publications
Latest Publications
- Open Access
- 1 January 2023
- Published by SAGE Publications in Cell Transplantation
- Vol. 32
Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial
Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of motor neurons. Multilineage-differentiating stress-enduring (Muse) cells are unique endogenous stem cells that show therapeutic effects on motor function in ALS mouse models. We conducted a single-center open phase II clinical trial to evaluate the safety and clinical effects of repeated intravenous injections of an allogenic Muse cell-based product, CL2020, in patients with ALS. Five patients with ALS received CL2020 intravenously once a month for a total of six doses. The primary endpoints were safety and tolerability, and the secondary endpoint was the rate of change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score. In addition, serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), sphingosine-1-phosphate (S1P), cerebrospinal fluid chitotriosidase-1 (CHIT-1), and neurofilament light chain (NfL) levels were evaluated. The CL2020 treatment was highly tolerated without serious side effects. The ALSFRS-R score change trended upward at 12 months post-CL2020 treatment compared with that at 3 months pre-administration, but the difference was not statistically significant. Among five patients diagnosed with ALS, three exhibited a decrease in the rate of ALSFRS-R score change, one demonstrated an increase, and another showed no change. In addition, the patients’ serum IL-6 and TNF-α levels and cerebrospinal fluid CHIT-1 and NfL levels increased for up to 6 months post-treatment; however, their serum S1P levels continuously decreased over 12 months. These findings indicate a favorable safety profile of CL2020 therapy. In the near future, a double-blind study of a larger number of ALS patients should be conducted to confirm the efficacy of ALS treatment with CL2020.
- 1 January 2023
- Published by SAGE Publications in Cell Transplantation
- Vol. 32
Open AccessSafety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial
Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of motor neurons. Multilineage-differentiating stress-enduring (Muse) cells are unique endogenous stem cells that show therapeutic effects on motor function in ALS mouse models. We conducted a single-center open phase II clinical trial to evaluate the safety and clinical effects of repeated intravenous injections of an allogenic Muse cell-based product, CL2020, in patients with ALS. Five patients with ALS received CL2020 intravenously once a month for a total of six doses. The primary endpoints were safety and tolerability, and the secondary endpoint was the rate of change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score. In addition, serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), sphingosine-1-phosphate (S1P), cerebrospinal fluid chitotriosidase-1 (CHIT-1), and neurofilament light chain (NfL) levels were evaluated. The CL2020 treatment was highly tolerated without serious side effects. The ALSFRS-R score change trended upward at 12 months post-CL2020 treatment compared with that at 3 months pre-administration, but the difference was not statistically significant. Among five patients diagnosed with ALS, three exhibited a decrease in the rate of ALSFRS-R score change, one demonstrated an increase, and another showed no change. In addition, the patients’ serum IL-6 and TNF-α levels and cerebrospinal fluid CHIT-1 and NfL levels increased for up to 6 months post-treatment; however, their serum S1P levels continuously decreased over 12 months. These findings indicate a favorable safety profile of CL2020 therapy. In the near future, a double-blind study of a larger number of ALS patients should be conducted to confirm the efficacy of ALS treatment with CL2020.
- 1 September 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 252-254
A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene
- 1 September 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 252-254
A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene
- 22 August 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 266-268
Japanese case of Charcot–Marie–Tooth disease type 2Z with severe retinitis pigmentosa
- 22 August 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 266-268
Japanese case of Charcot–Marie–Tooth disease type 2Z with severe retinitis pigmentosa
- 8 February 2022
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 42 (7) , 1322-1334
Efficacy and safety of spot heating and ultrasound irradiation on in vitro and in vivo thrombolysis models
The feasibility of transcranial sonothrombolysis has been demonstrated, although little is known about the relationships between thermal or mechanical mechanisms and thrombolytic outcomes. Therefore, the present study aims to reveal the effect and safety of temperature and ultrasound through in vitro and in vivo thrombolysis models. Artificial clots in microtubes were heated in a water bath or sonicated by ultrasound irradiation, and then clots weight decrease with rising temperature and sonication time was confirmed. In the in vitro thrombotic occlusion model, based on spot heating, clot volume was reduced and clots moved to the distal side, followed by recanalization of the occlusion. In the in vivo study, the common carotid artery of rats was exposed to a spot heater or to sonication. No brain infarct or brain blood barrier disruption was shown, but endothelial junctional dysintegrity and an inflammatory response in the carotid artery were detected. The present spot heating and ultrasound irradiation models seem to be effective for disintegrating clots in vitro, but the safety of the in vivo model was not fully supported by the data. However, the data indicates that a shorter time exposure could be less invasive than a longer exposure.
- 8 February 2022
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 42 (7) , 1322-1334
Efficacy and safety of spot heating and ultrasound irradiation on in vitro and in vivo thrombolysis models
The feasibility of transcranial sonothrombolysis has been demonstrated, although little is known about the relationships between thermal or mechanical mechanisms and thrombolytic outcomes. Therefore, the present study aims to reveal the effect and safety of temperature and ultrasound through in vitro and in vivo thrombolysis models. Artificial clots in microtubes were heated in a water bath or sonicated by ultrasound irradiation, and then clots weight decrease with rising temperature and sonication time was confirmed. In the in vitro thrombotic occlusion model, based on spot heating, clot volume was reduced and clots moved to the distal side, followed by recanalization of the occlusion. In the in vivo study, the common carotid artery of rats was exposed to a spot heater or to sonication. No brain infarct or brain blood barrier disruption was shown, but endothelial junctional dysintegrity and an inflammatory response in the carotid artery were detected. The present spot heating and ultrasound irradiation models seem to be effective for disintegrating clots in vitro, but the safety of the in vivo model was not fully supported by the data. However, the data indicates that a shorter time exposure could be less invasive than a longer exposure.
- 1 November 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (1) , 30-34
Three cases of GFAP astrocytopathy, one with bilateral ovarian teratoma
- 1 November 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (1) , 30-34
Three cases of GFAP astrocytopathy, one with bilateral ovarian teratoma
- 1 September 2021
- Published by Elsevier in Brain Research
- Vol. 1766, 147516
Neuroprotective effects of Scallop-derived plasmalogen in a mouse model of ischemic stroke
- 1 September 2021
- Published by Elsevier in Brain Research
- Vol. 1766, 147516
Neuroprotective effects of Scallop-derived plasmalogen in a mouse model of ischemic stroke
- 17 August 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (6) , 470-473
A case of rheumatoid meningoencephalitis induced by pembrolizumab
- 17 August 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (6) , 470-473
A case of rheumatoid meningoencephalitis induced by pembrolizumab
- Open Access
- 14 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-3
Author Correction: Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 14 June 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-3
Open AccessAuthor Correction: Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 1 March 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (3) , 105583
4-Hydroxyl-2-Nonenal Localized Expression Pattern in Retrieved Clots is Associated with Large Artery Atherosclerosis in Stroke Patients
- 1 March 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (3) , 105583
4-Hydroxyl-2-Nonenal Localized Expression Pattern in Retrieved Clots is Associated with Large Artery Atherosclerosis in Stroke Patients
- 23 February 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (3) , 218-222
Positive baseline behavioral and psychological symptoms of dementia predict a subsequent cognitive impairment in cognitively normal population
Background: Because behavioral and psychological symptoms of dementia (BPSD) are sometimes prodromal symptoms of dementia, it is important to investigate the relationship between BPSD and subsequent cognitive decline.Methods: We examined the cognitive and affective functions of 76 cognitively normal subjects at initial assessment (baseline) and 1‐year follow‐up. Cognitive function was assessed using clinical dementia rating (CDR) and Mini‐Mental State Examination (MMSE), and affective function was assessed using Abe's BPSD score (ABS) and mild behavioral impairment (MBI).Results: Although there was no change in MMSE, ABS, or MBI after 1 year, the mean CDR score of 0 at baseline increased to 0.1 ± 0.2 at 1‐year follow‐up (**P < 0.01 vs baseline). No significant change in MMSE was found in both baseline ABS and MBI positive‐ or negative‐groups. In contrast, baseline MBI‐dependent CDR change showed a 13.2% of worsening in MBI‐negative subjects and a 62.5% of MBI‐positive subjects (††P < 0.01), but ABS not.Conclusion: The present data indicate that positive baseline BPSD with MBI was closely related to a subsequent CDR exacerbation. Examining BPSD may be useful for screening cognitively normal population for subsequent dementia development in local communities.
- 23 February 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (3) , 218-222
Positive baseline behavioral and psychological symptoms of dementia predict a subsequent cognitive impairment in cognitively normal population
Background: Because behavioral and psychological symptoms of dementia (BPSD) are sometimes prodromal symptoms of dementia, it is important to investigate the relationship between BPSD and subsequent cognitive decline.Methods: We examined the cognitive and affective functions of 76 cognitively normal subjects at initial assessment (baseline) and 1‐year follow‐up. Cognitive function was assessed using clinical dementia rating (CDR) and Mini‐Mental State Examination (MMSE), and affective function was assessed using Abe's BPSD score (ABS) and mild behavioral impairment (MBI).Results: Although there was no change in MMSE, ABS, or MBI after 1 year, the mean CDR score of 0 at baseline increased to 0.1 ± 0.2 at 1‐year follow‐up (**P < 0.01 vs baseline). No significant change in MMSE was found in both baseline ABS and MBI positive‐ or negative‐groups. In contrast, baseline MBI‐dependent CDR change showed a 13.2% of worsening in MBI‐negative subjects and a 62.5% of MBI‐positive subjects (††P < 0.01), but ABS not.Conclusion: The present data indicate that positive baseline BPSD with MBI was closely related to a subsequent CDR exacerbation. Examining BPSD may be useful for screening cognitively normal population for subsequent dementia development in local communities.